Acquisitions (Details) - USD ($) $ in Millions		1 Months Ended	3 Months Ended
		Jan. 31, 2017	Mar. 31, 2017	Mar. 31, 2016	Jan. 03, 2017	Dec. 31, 2016
Cost of sales			$ 1,327.7	$ 1,323.0
Interest Expense			46.6	43.4
Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual			40.8
Payments to Acquire Businesses, Net of Cash Acquired			882.1	0.0
Goodwill			4,188.0			$ 3,972.7
Acquired in-process research and development			857.6	0.0
Purchased in-process research and development			831.8	0.0
Boehringer Ingelheim Vetmedica, Inc.'s U.S. Vaccine Portfolio [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory					$ 105.2
Business Combination, Consideration Transferred		$ 882.1
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	[1]				404.0
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets					33.0
Business Combination, Consideration Transferred					882.1
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life		10 years
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment					156.2
Goodwill	[2]				184.4
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities					(0.7)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net					$ 697.7
CoLucid Pharmaceuticals [Member]
Acquired in-process research and development			857.6
Purchased in-process research and development			831.8
Noncash or Part Noncash Acquisition, Value of Liabilities Assumed			25.8
Corporate, Non-Segment [Member]
Amortization of Intangible Assets			176.1	172.5
Acquired in-process research and development			857.6	0.0
Corporate, Non-Segment [Member] | Fair Value Adjustment to Inventory [Member]
Cost of sales			$ 10.4	$ 0.0

[1] (1) These intangible assets, which are being amortized to cost of sales on a straight-line basis over their estimated useful lives, were expected to have a weighted average useful life of 10 years.

[2] (2) The goodwill recognized from this acquisition is attributable primarily to expected synergies from combining the operations of BIVIVP with our legacy animal health business, future unidentified projects and products, and the assembled workforce of BIVIVP. We anticipate that the goodwill associated with this acquisition will be deductible for tax purposes.